Research programme: RecA inhibitors - Synereca Pharmaceuticals

Drug Profile

Research programme: RecA inhibitors - Synereca Pharmaceuticals

Latest Information Update: 26 Sep 2014

Price : $50

At a glance

  • Originator Synereca Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Rec A recombinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Bacterial infections

Most Recent Events

  • 26 Sep 2014 Preclinical research is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top